

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

REMOVAL OF STOCK MARKER “B”

Reference is made to the announcement of 3D Medicines Inc. (the “**Company**”) dated May 9, 2023 (the “**Announcement**”) with respect to the approval granted by the Stock Exchange on May 9, 2023 for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules to the Company. Unless otherwise defined, capitalised terms herein shall have the same meanings as those defined in the Announcement.

Further to the Announcement, the Company wishes to advise investors that the “B” marker will cease to be affixed to the Company’s stock short name from May 18, 2023.

By order of the Board

3D Medicines Inc.

Dr. Gong Zhaolong

Chairman of the Board and Executive Director

Hong Kong, May 12, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.